gp100 (intron 4)

gp100 (intron 4) is a synthetic peptide fragment derived from the intron 4 region of the human gp100 glycoprotein, a melanocyte differentiation antigen widely studied in the context of melanoma biology and immunology. As a peptide-based research tool, it serves as a highly specific probe for investigating antigen processing, T cell recognition, and the molecular mechanisms underlying immune responses to melanoma-associated antigens. The unique sequence of gp100 (intron 4) makes it particularly valuable in studies focused on the identification of peptide epitopes, MHC binding, and the functional analysis of antigen presentation pathways. Its use is central to advancing understanding in both basic immunological research and applied peptide science.

Epitope mapping: Researchers employ this peptide in epitope mapping studies to delineate the precise regions of the gp100 protein recognized by T cells. By exposing immune cells to the intron 4-derived sequence, investigators can characterize the minimal peptide motifs required for T cell activation, providing critical insights into antigen-specific immune recognition. Such studies facilitate the identification of immunodominant epitopes, which are essential for understanding host-pathogen interactions and the development of antigen-targeted immunological assays.

Antigen processing and presentation studies: The intron 4 peptide is used to probe the mechanisms of antigen processing and MHC class I and II presentation. By incorporating this peptide into in vitro systems, scientists can assess how the antigen is processed by proteasomes and loaded onto MHC molecules, thereby elucidating the molecular determinants that govern peptide presentation to T lymphocytes. These investigations are foundational for optimizing antigen delivery systems and for dissecting the cellular machinery involved in immune surveillance.

Peptide-MHC binding assays: In biochemical and immunological workflows, the gp100 (intron 4) peptide is utilized in binding assays to evaluate its affinity and stability with various MHC alleles. Such assays are instrumental in quantifying the peptide's binding kinetics, which in turn inform the design of synthetic peptide libraries and the selection of candidate epitopes for downstream immunological applications. The data generated from these experiments contribute to predictive models of peptide-MHC interactions and improve the accuracy of computational epitope prediction tools.

Functional T cell assays: The peptide serves as a defined stimulus in functional assays designed to assess T cell activation, proliferation, and cytokine production. By presenting the intron 4 sequence to antigen-specific T cell populations, researchers can measure cellular responses such as interferon-gamma secretion, cytotoxic activity, and expansion kinetics. These assays are critical for evaluating the immunogenicity of peptide antigens, validating T cell receptor specificity, and benchmarking immune responses in experimental models.

Peptide synthesis validation: The well-characterized sequence of gp100 (intron 4) also makes it a valuable standard in peptide synthesis and analytical quality control. Laboratories utilize this peptide to calibrate and validate peptide synthesis protocols, chromatographic separation methods, and mass spectrometry analyses. Its defined structure and immunological relevance enable it to serve as a reference compound for benchmarking performance across different peptide production and analytical platforms, supporting reproducibility and consistency in peptide-based research.

1. High fat diet and GLP-1 drugs induce pancreatic injury in mice

2. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

3. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

4. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors

5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists